Walleye Trading LLC purchased a new position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 38,490 shares of the company’s stock, valued at approximately $318,000. Walleye Trading LLC owned approximately 0.06% of Kezar Life Sciences at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. raised its stake in Kezar Life Sciences by 392.1% during the first quarter. Victory Capital Management Inc. now owns 1,752,707 shares of the company’s stock valued at $29,130,000 after buying an additional 1,396,503 shares in the last quarter. State Street Corp increased its holdings in shares of Kezar Life Sciences by 67.4% in the 1st quarter. State Street Corp now owns 2,242,554 shares of the company’s stock valued at $37,271,000 after acquiring an additional 902,588 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kezar Life Sciences by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 2,228,084 shares of the company’s stock valued at $37,031,000 after acquiring an additional 336,669 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Kezar Life Sciences during the 2nd quarter valued at approximately $2,004,000. Finally, BlackRock Inc. lifted its stake in Kezar Life Sciences by 7.8% during the first quarter. BlackRock Inc. now owns 2,897,074 shares of the company’s stock worth $48,150,000 after purchasing an additional 210,050 shares during the last quarter. Institutional investors own 91.01% of the company’s stock.
Kezar Life Sciences Stock Performance
Shares of KZR stock opened at $7.41 on Friday. The company has a market cap of $506.68 million, a P/E ratio of -7.34 and a beta of 0.19. The business has a 50 day moving average of $8.02 and a two-hundred day moving average of $8.07. Kezar Life Sciences, Inc. has a 52 week low of $4.30 and a 52 week high of $18.55. The company has a quick ratio of 31.15, a current ratio of 31.15 and a debt-to-equity ratio of 0.03.
Wall Street Analysts Forecast Growth
Insider Buying and Selling
In related news, major shareholder Morningside Venture Investment sold 28,700 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $8.78, for a total transaction of $251,986.00. Following the completion of the transaction, the insider now directly owns 6,080,352 shares in the company, valued at approximately $53,385,490.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 7.80% of the company’s stock.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.